Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CDC42 | P60953 | 1/20 | 0.47 |
| ▸ | RAC1 | P63000 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5088739 | 0.87 | FFAR1 (0.59) | LDHAALDH1A1NPC1MAPTRAB9A | |
| SCHEMBL13661683 | 0.85 | ACACB (0.46) | CYP1A2CA1CA2SLC2A1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7261129 | 0.84 | ACACB (0.45) | CYP1A2SLC2A1ALDH1A1AOC3KMT2A | |
| SCHEMBL11928257 | 0.84 | ALOX5 (0.50) | CA1CA2SLC2A1ALDH1A1AOC3 | |
| SCHEMBL11441436 | 0.82 | LDHA (0.50) | LDHAAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL28656346 | 0.80 | NPSR1 (0.46) | LDHAAKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL29173105 | 0.80 | TDP1 (0.53) | PTGS1L3MBTL1AOC3 | |
| SCHEMBL29173106 | 0.80 | TDP1 (0.53) | PTGS1L3MBTL1AOC3 | |
| SCHEMBL18920459 | 0.79 | CHRNA7 (0.50) | ALDH1A1ALOX5 | |
| SCHEMBL18946105 | 0.79 | CHRNA7 (0.50) | ALDH1A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163698-B2 | Dolastatin 15 derivatives | ABBOTT GMBH & CO. KG (DE) | 2012-04-24 | — | — | US | claimed |
| US-20100099843-A1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO. KG (DE) | 2010-04-22 | — | — | US | claimed |
| US-20130046077-A1 | DOLASTATIN 15 DERIVATIVES | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2013-02-21 | — | — | US | disclosed |
| US-8163698-B2 | Dolastatin 15 derivatives | ABBOTT GMBH & CO. KG (DE) | 2012-04-24 | — | — | US | disclosed |
| US-20100099843-A1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO. KG (DE) | 2010-04-22 | — | — | US | disclosed |
| US-7662786-B2 | oligopeptides; anticarcinogenic agent; good water solubility and cost effective; , B, D, E, F, G and K are alpha -amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as,an amino group, an N-substituted amino group, a beta -hydroxylamino group, an alkoxy group | ABBOTT GMBH & CO. KG (DE) | 2010-02-16 | — | — | US | disclosed |
| US-20060270606-A1 | Dolastatin 15 derivatives | ABBOTT GMBH & CO., KG (DE) | 2006-11-30 | — | — | US | disclosed |
| US-7084110-B2 | Anticarcinogenic agents for treating cancer; pentapeptides, hexapeptides, heptapeptides, oligopeptides | ABBOTT GMBH & CO., KG (DE) | 2006-08-01 | — | — | US | disclosed |
| EP-0991658-B1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO KG (DE) | 2005-12-28 | — | — | EP | disclosed |
| US-6458765-B1 | POLYPEPTIDES AS ANTICANCER AGENTS AND AGAINST CELL PROLIFERATION | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-01 | — | — | US | disclosed |
| US-6143721-A | FOR TREATING CANCER IN MAMMALS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099843-A1 | DOLASTATIN 15 DERIVATIVES | DDOST, DBI, DAO | LDHA 349/4885AKR1C3 273/4885AKR1C2 145/4885 |
| US-20060270606-A1 | Dolastatin 15 derivatives | DDOST, DBI, DAO | LDHA 349/4885AKR1C3 273/4885AKR1C2 145/4885 |
| US-20130046077-A1 | DOLASTATIN 15 DERIVATIVES | DDOST, DBI, DAO | LDHA 349/4885AKR1C3 273/4885AKR1C2 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.